Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Jamaati
  IRCT20151227025726N1		 RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
25/25 suggested
  • inconclusive 19 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 38 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 3.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
Munch (COVID-STEROID)
  NCT04348305		 RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
16/14 no results
    CAPE-COVID
          NCT02517489    		 RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
    		76/73 inconclusive
    • inconclusive 29 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
    CODEX (Tomazini)
          NCT04327401    		 RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
    		151/148 inconclusive
      DEXA-COVID19
              NCT04325061      		 RCTdexamethasonestandard of careCOVID-19 severe or criticallylow
      		7/12 inconclusive
        Edalatifard
                  IRCT20200404046947N1        		 RCTmethylprednisolonestandard of careCOVID-19 severe or criticallyhigh
        		34/34 suggested
        • suggested 71 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
        • suggested 11.0-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
        REMAP-CAP, fixed 7-day course
                  NCT02735707        		 RCTHydrocortisonestandard of careCOVID-19 severe or criticallyhigh
        		143/108 safety concern
        • inconclusive 43 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
        • statistically significant 1.7-fold increase in death or ventilation but with a low degree of certainty due to high risk of bias
        REMAP-CAP, shock-dependent course
                  NCT02735707        		 RCTcorticosteroidsstandard of careCOVID-19 severe or criticallyhigh
        		152/108 inconclusive
        • inconclusive 22 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
        Steroids-SARI
                  NCT04244591        		 RCTmethylprednisolonestandard of careCOVID-19 severe or criticallysome concern
        		24/23 inconclusive
          3 studies excluded by filtering options (0 RCT / 3 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons